Aspire Submits Registration Statement for US IPO

Feb.22.2023
Aspire Submits Registration Statement for US IPO
Aspire, an e-cigarette and CBD product company, submitted registration to list on NASDAQ with an expected $155.25 million in funding.

On February 20th, the electronic cigarette and CBD product company, Aspire, filed a registration statement to go public on the US stock market.


The company intends to go public on the NASDAQ stock exchange, with a proposed maximum share price of $9 and the aim of raising $155.25 million by issuing 17.25 million shares. The registration statement provides details on the company's current operations, risk factors, and equity structure.


The parent company of Aspire, a business department, is a manufacturer of vape and CBD products. The total global retail sales of vape products from 2015 to 2020 and the retail sales forecast for 2021 to 2024 are also presented in the registration document (see chart below).


Source: US Securities and Exchange Commission


According to data, during the early days of the company's establishment (2015-17), an open system was more welcomed by the market. However, since the gradual replacement of open vaping systems with closed ones, closed systems have become the mainstream in the market and surpassed open systems in 2019. That year, the global sales of closed vaping systems reached $9.688 billion, surpassing open systems' $8.392 billion.


The company predicts that closed systems will continue to dominate the market and that global vape sales will reach $66.8 billion by 2023.


Since 2019, the company has been expanding its CBD market in the United States and Canada. In 2020, the global sales of cannabis products reached $2.9 billion.


Source: U.S. Securities and Exchange Commission


In addition, the company also undertakes OEM/ODM business for electronic atomization systems.


According to Aspire's registration document, the company's main market is Europe, with the European market accounting for 61% of the company's total performance in 2020, followed by 22.6% in the United States. Their efforts to expand in the Asia-Pacific market have been significant, increasing from 0.1% in 2019 to 9.5%.


Source: U.S. Securities and Exchange Commission.


The risk factors listed in the registration statement of the company are as follows:


Existing and newly enacted laws, regulations, and policies could present barriers to the company's future business operations and have significant adverse effects. Currently, the company can only legally sell one product, Nautilus Prime, in the US, which accounted for less than 11% of the company's US revenues in the year ending June 30, 2020. As a result, the company can no longer sell products that accounted for more than 89% of their US revenues in that same period, leading to a decline in US sales in the six months ending December 31, 2020. The market for cannabis vaporization products is still immature, with most sales occurring in the US, and expansion in the US or globally is not guaranteed. Recently, joint statements from the US Securities and Exchange Commission and the Public Company Accounting Oversight Board, proposed rule changes from NASDAQ, and a bill passed by the US Senate have all called for stricter standards when evaluating the qualifications of auditors for emerging market companies, especially those auditors that are not subject to PCAOB inspections outside of the US. These developments could increase uncertainty around the company's issuances. If there is evidence to suggest or research to show that the use of electronic vaporization or cannabis products poses long-term health risks, the use of such products could significantly decrease, which would have a substantial adverse impact on the company's business, financial condition, and operating performance. The company's operations entail inherent risks and uncertainties, including developments in regulatory environments, medical discoveries, and the market's acceptance of electronic cigarette devices. The company faces potential adverse effects due to sales, product liability, and user complaints. Misuse or abuse of the company's products could lead to potential adverse health effects, leading to complaints, product liability claims, and negative publicity. The company faces competition in the electronic vaporization industry, including larger, more well-known companies with a significantly larger market share, and Aspire may not effectively compete. In addition, widespread outbreaks of diseases, natural disasters, or improper behavior by employees or distributors could harm the company's interests and reputation and have an adverse impact on its business operations.


2FIRSTS will continue to follow this topic and provide timely updates. Stay tuned for our latest coverage.


Reference:


Aspire has filed a registration statement with the U.S. Securities and Exchange Commission.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

US ITC Judge Finds Glas Infringed Two JUUL Vape Patents, Recommends Restrictions on Related Imports——Glas Received FDA Marketing Authorization for Four Vape Pods in May 2026; Proposed Restrictions Remain Under Commission Review
US ITC Judge Finds Glas Infringed Two JUUL Vape Patents, Recommends Restrictions on Related Imports——Glas Received FDA Marketing Authorization for Four Vape Pods in May 2026; Proposed Restrictions Remain Under Commission Review
A U.S. International Trade Commission (USITC) administrative law judge issued an initial determination on October 20, 2026, finding that certain Glas vaping devices, cartridges and components infringed 12 claims across two patents asserted by JUUL, constituting a violation of Section 337 of the Tariff Act of 1930. The judge recommended a limited exclusion order and a cease and desist order against the Glas respondents. Five months earlier, the FDA authorized four Glas e-cigarette pods, including mango, blueberry and two menthol variants. The patent investigation concerns device and cartridge structures and is separate from FDA premarket review. The proposed import restrictions have not become final, and their product-level scope remains unresolved.
company
Nov.05
Italian Financial Police Seize 4.3 Million E-Cigarettes and Smoking Accessories; 28 Reported to Judicial Authorities Across Operations
Italian Financial Police Seize 4.3 Million E-Cigarettes and Smoking Accessories; 28 Reported to Judicial Authorities Across Operations
Italy's Guardia di Finanza announced on October 28 that officers in Latina province had seized approximately 4.3 million e-cigarettes and smoking accessories at an unauthorized warehouse in an operation involving restrictions on the possession and sale of tobacco-related products. Another 300,000 suspected counterfeit or unsafe items were confiscated during separate inspections, bringing total seizures across the operations to more than 4.6 million products. Twenty-eight people were reported to judicial authorities over suspected smuggling and counterfeiting offenses. Officials did not disclose separate vape quantities, the value of the merchandise or alleged violations associated with individual brands.
Enforcement
Oct.29
Product | KUMI SCENIC 50K Offers Nicotine and 6-Methyl Nicotine Versions as 6-MN Products Appear in Multiple U.S. State Directories, With Louisiana Listing FDA Exemption
Product | KUMI SCENIC 50K Offers Nicotine and 6-Methyl Nicotine Versions as 6-MN Products Appear in Multiple U.S. State Directories, With Louisiana Listing FDA Exemption
An October 2026 review of U.S. state vapor product directories found KUMI 6 SCENIC 50K listed in Louisiana and Nebraska. Louisiana classifies 20 related product entries as “FDA EXEMPTION.” The SCENIC platform is marketed in both conventional nicotine-salt and NoNic6 formulations, each advertised with 22mL e-liquid capacity and up to 50,000 puffs. U.S. wholesaler Midwest Goods listed both versions in August 2025 with a suggested retail price of $19.99 each. The NoNic6 version is associated with 6-methylnicotine and is also marketed by some distributors as “nicotine-free.”
product
Oct.27
Global Nicotine-Pouch E-Commerce Group Haypp Shuts Sweden’s Snusnetto Over Age Verification as Identity Checks Become Industry Infrastructure for New Nicotine Products
Global Nicotine-Pouch E-Commerce Group Haypp Shuts Sweden’s Snusnetto Over Age Verification as Identity Checks Become Industry Infrastructure for New Nicotine Products
Sweden's Supreme Administrative Court has declined to hear an appeal over age verification for tobacco and nicotine products collected from parcel lockers, leaving in place a lower-court ruling that geo-located BankID verification is insufficient to securely verify the actual recipient. Haypp Group has stopped tobacco and nicotine sales through Snusnetto and is deploying a new system across its other Swedish e-commerce sites to verify the age of the person who actually opens the locker and receives the shipment. The change comes as age verification across next-generation nicotine products expands from purchase checks into retail, delivery and, for some e-cigarettes, device access itself.
Regulations
Oct.20
2Firsts Hosts China Market Forum at InterTabac as Global Industry Attention to China’s Tobacco Sector Deepens
2Firsts Hosts China Market Forum at InterTabac as Global Industry Attention to China’s Tobacco Sector Deepens
On September 16, 2Firsts hosted a China-focused industry forum during InterTabac in Dortmund, bringing together more than 30 participants from North America, Europe, India, South Korea and other markets. The session covered traditional tobacco, next-generation products, exports, technology, regulation and supply chains, while examining how China’s tobacco sector operates, where its transformation may be heading, and why its growing role matters increasingly to companies across the global tobacco and nicotine industry.
Sep.21
Russia's State Duma Passes Tobacco and Nicotine Ingredient Disclosure Bill, Targeting 2027 End to Trade-Secret Protection for Certain Harmful Ingredient Data
Russia's State Duma Passes Tobacco and Nicotine Ingredient Disclosure Bill, Targeting 2027 End to Trade-Secret Protection for Certain Harmful Ingredient Data
Russia's State Duma passed a government-sponsored amendment on November 11, 2026, by 414 votes to none, seeking to prevent businesses from classifying information on the presence and number of types of certain harmful ingredients in tobacco and nicotine-containing products as trade secrets. The measure covers ingredients capable of increasing nicotine dependence or exhibiting toxic, carcinogenic, mutagenic or reproductive toxicity, including substances that acquire such properties during heating or smoldering. Bill No. 1286415-8 would amend Article 5 of Federal Law No. 98-FZ on Commercial Secrets and is scheduled to take effect on January 1, 2027. The bill has cleared all three readings in the State Duma but has not completed the remaining legislative procedures.
Regulations
Nov.12 by 2Firsts Perspectives